3 Promising European Penny Stocks With Market Caps Below €400M

European markets have recently faced challenges, with the pan-European STOXX Europe 600 Index experiencing a decline amid rising oil prices, geopolitical tensions, and inflationary pressures. Despite these headwinds, investors continue to explore opportunities in lesser-known areas of the market. Penny stocks, often representing smaller or newer companies, remain relevant as they can offer unique value and growth potential. In this article, we will explore three European penny stocks that stand out for their financial strength and potential for long-term success.

Let's dive into some prime choices out of the screener.

Deceuninck (ENXTBR:DECB)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Deceuninck NV is involved in the design, manufacture, and recycling of multi-material window, door, and building solutions across North America, Europe, Turkey, and other international markets with a market cap of €334.55 million.

Operations: The company's revenue is primarily derived from Window and Door Systems (€745.21 million), followed by Home Protection (€38.18 million) and Outdoor Living (€25.88 million).

Market Cap: €334.55M

Deceuninck NV's recent performance highlights its potential as a penny stock with solid fundamentals. The company reported significant revenue growth to €420.07 million for the first half of 2026, with net income more than doubling compared to the previous year. Its debt is well-covered by operating cash flow, and it maintains a satisfactory net debt to equity ratio of 31.7%. Despite low return on equity at 10.7%, Deceuninck offers good value with a price-to-earnings ratio below the Belgian market average, and its earnings growth has outpaced industry averages significantly over the past year.

• Click here and access our complete financial health analysis report to understand the dynamics of Deceuninck.
• Understand Deceuninck's earnings outlook by examining our growth report.

Lemonsoft Oyj (HLSE:LEMON)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Lemonsoft Oyj is a software company that designs, develops, and delivers enterprise resource planning software solutions in Finland and internationally with a market cap of €88.62 million.

Operations: The company generates revenue of €29.77 million from its Software & Programming segment.

Market Cap: €88.62M

Lemonsoft Oyj, with a market cap of €88.62 million, demonstrates potential in the penny stock arena through its solid financial performance and growth prospects. The company reported increased earnings for the first half of 2026, with net income rising to €2.1 million from €1.53 million a year ago, and improved profit margins at 17.1%. Although short-term assets fall short of covering both long-term and short-term liabilities, Lemonsoft's debt is well-covered by operating cash flow. Despite high share price volatility recently, its earnings growth surpasses industry averages significantly over the past year.

• Dive into the specifics of Lemonsoft Oyj here with our thorough balance sheet health report.
• Explore Lemonsoft Oyj's analyst forecasts in our growth report.

Biovica International (OM:BIOVIC B)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Biovica International AB is a biotech company that develops and commercializes blood-based biomarker assays for monitoring cancer progression, with operations in the European Union, the United States, and Asia, and has a market cap of SEK108.30 million.

Operations: The company generates revenue of SEK14.93 million from its biotechnology segment.

Market Cap: SEK108.3M

Biovica International AB, with a market cap of SEK108.30 million, operates in the biotech sector and is currently pre-revenue despite generating SEK14.93 million from its biotechnology segment. The company remains unprofitable and has experienced increased losses over the past five years, though it benefits from having no debt and sufficient short-term assets to cover liabilities. Recent developments include a follow-on equity offering raising SEK29.19 million and securing new contracts under a Master Services Agreement for DiviTum TKa testing, which is gaining traction as a prognostic biomarker in cancer treatment monitoring across various studies and collaborations globally.

• Take a closer look at Biovica International's potential here in our financial health report.
• Examine Biovica International's earnings growth report to understand how analysts expect it to perform.

Turning Ideas Into Actions

• Explore the 300 names from our European Penny Stocks screener here.
• Looking For Alternative Opportunities? AI is about to change healthcare. These 130 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com